Ventripoint Diagnostics Launches Targeted Congenital Heart Defect Marketing Program, Setting Stage for Multi-Segment Growth
(TheNewswire)
Toronto, Ontario – TheNewswire - August 15, 2025 –Ventripoint Diagnostics Ltd. (“Ventripoint” or the“Corporation”),(TSXV:VPT; OTC:VPTDF)a leader in AI-powered heart analysis solutions,today announced the launch of a targeted marketing program focused onthe diagnosis and monitoring of congenital heart defects (CHD). Theinitiative is designed to solidify Ventripoint’s leadership positionin this high-need clinical area, while laying the foundation forexpansion into other rapidly growing segments includingcardio-oncology, pulmonary hypertension, heart failure, and valvularheart disease.
The new program will spotlight the Company’s flagshipVMS+™ system, which delivers MRI-comparable volumetric andfunctional cardiac measurements using standard echocardiography. Thiscapability eliminates many of the patient and workflow barriersassociated with cardiac MRI - particularly critical for CHD patients,who often require frequent monitoring from infancy throughadulthood.
“CHD patients face a lifetime of imaging, yet manycannot access MRI due to cost, availability, or clinicallimitations,” said Hugh MacNaught, President and CEO of VentripointDiagnostics. “Our VMS+ technology solves that challenge by enablingfast, accurate, and comfortable assessments using widely availableultrasound equipment. By leading in CHD, we are also building theclinical credibility and installed base needed to accelerate adoptionin other high-value segments.”
The CHD-focused marketing program will include:
Collaboration with Industry Partners – Continuing toactively work with partners such as ASCEND Cardiovascular tocross-market and promote AI enhanced echocardiographysolutions.
Specialized Clinical Education – Building on ourrelationships with pediatric and adult congenital cardiology centersto demonstrate workflow integration and patient benefits.
Patient Advocacy Engagement – Continuing thecollaboration with the Ollie Hinkel Heart Foundation and developingrelationships with other CHD advocacy organizations to increaseawareness of advanced, accessible imaging options.
Key Opinion Leader (KOL) Partnerships – Working withour clinical advisors to publish CHD case studies and peer-revieweddata that reinforce VMS+ as the standard of care for functionalcardiac assessment without MRI.
By establishing a leadership position in CHD,Ventripoint expects to accelerate uptake in additional clinical areaswhere fast, non-invasive, and accurate cardiac volumetric analysis isin demand - such as monitoring heart damage in cancer patients(cardio-oncology), tracking right heart changes in pulmonaryhypertension, assessing cardiac performance in heart failure, andassessing suitability of patients for valve repair and replacementprocedures in addition to monitoring outcomes.
“Each of these markets represents a significantgrowth opportunity, but CHD offers a unique platform for proving ourvalue proposition in the most challenging and underserved patientpopulation,” added Hugh MacNaught. “From there, our addressablemarket expands exponentially.”
Ventripoint will provide updates on program milestonesand commercial progress in its upcoming quarterlycommunications.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary knowledge-based reconstruction technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all of Ventripoint's productsthat guide our future developments. In addition, VMS+ is versatile andcan be used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
For further information, pleasecontact:
Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201
Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' andsimilar expressions are intended to identify forward-lookinginformation or statements. The forward-looking statements andinformation are based on certain key expectations and assumptions madeby the Corporation. Although the Corporation believes that theexpectations and assumptions on which such forward-looking statementsand information are based are reasonable, undue reliance should not beplaced on the forward-looking statements and information because theCorporation can give no assurance that they will prove to becorrect.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in theCorporation's most recent annual management's discussion andanalysis that is available on theCorporation's profile on SEDAR+ at www.sedarplus.ca. Readersare cautioned that the foregoing list of factors is not exhaustive.The forward-looking statements included in this news release areexpressly qualified by this cautionary statement. The forward-lookingstatements and information contained in this news release are made asof the date hereof and the Corporation undertakes no obligation toupdate publicly or revise any forward-looking statements orinformation, whether as a result of new information, future events orotherwise, unless so required by applicable securities laws.
Copyright (c) 2025 TheNewswire - All rights reserved.
